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Introduction
Epilepsy affects approximately 0.6% to 0.8% of the gen-
eral population and it is a disorder with strong genetic con-
tributions [1]. Globally, the idiopathic epilepsy, a term in-
troduced in 1985, within the International League Against 
Epilepsy (ILAE)’s proposal for classification of epilepsies 
and epileptic syndrome [2], means epilepsy of genetic origin 
or without a definite structural, metabolic, infective, or im-
mune cause / or when diagnostic assessment did not reveal 
a causative factor) – ranked the 5th among neurological dis-
orders after stroke, migraine, dementia, and meningitis and 
even the 2nd in some particular areas (southern sub-Saharan 
Africa) [3].
The incidence of epilepsy is nearly 70 per 100000 chil-
dren younger than 2 years and genetic epilepsies account 
for more than 0.4% of the general population, constituting 
30% of all epilepsies [4]. A study on a larger group of severe 
epilepsy cases starting before the 18month-age found an in-
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Abstract
Background: Epilepsy affects around 1% of the general population. With already acknowledged strong genetic contributions, >50% of epilepsy cases 
still remain undiagnosed. This is primordially due to the multifactorial condition of epilepsy that makes it a challenge to select the optimal genetic test 
for each specific case. Recently, next-generation sequencing (NGS) led to massive gene discovery, including epilepsy that also imposed serious financial 
burdens on healthcare systems. This study review highlights the progress in the field of epilepsy genetics and argues on how the genetic architecture 
of common epilepsies is progressively being unraveled. Since the 1995 finding of CHRNA4 mutation, more than 500 genes were estimated to play a 
significant role in epilepsy. To date, the majority of diagnostic genetic testing is conducted in the pediatric population, while the utility of such testing is 
less well understood in adults with epilepsy. A broad range in the diagnostic rate of NGS, especially of the Whole Exome Sequencing (WES), in epilepsy 
has been described. However, NGS introduces new challenges, yet to be resolved.
Conclusions: Epilepsy’s genetic background is nowadays undeniable; however, the complexity of this condition makes it difficult to be solved. WES 
has increasingly been used to uncover the role of the coding genetic material in the human genome and is nowadays considered one of the most cost-
effective genetic tests for epilepsy, being a prerequisite for personalized treatment approaches and for reducing the epilepsy patient’s “diagnostic odyssey”.
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Globally, in 2016, there were 45.9 million patients with 
all-active epilepsy (both idiopathic and secondary epilepsy 
globally). Of these patients, 24 million had active idiopathic 
epilepsy (prevalence 326.7 per 100000 population) [8].
Idiopathic epilepsy accounted for 0.23% of deaths and 
0.56% of disability-adjusted life-years (DALYs) from all 
causes. Global age-standardized mortality rates of idio-
pathic epilepsy were 1.74 per 100 000 population (1.40 per 
100000 population for women and 2.09 per 100000 popula-
tion for men) [8]. A decrease in death and DALYs rates in 
patients with epilepsy between 1990 and 2016 was recorded, 
however the changes varied across geographical areas and 
based on the available data within countries. Furthermore, 
changes were linked to the socio-demographic develop-
ment status, which should prompt more action in economi-
cally deprived areas. The success of reducing the burden of 
idiopathic epilepsy relies mostly on access to treatment and 
diagnostic techniques [3, 8].
Several diseases and injuries are involved in the origin of 
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epileptic seizures, showing a variable distribution worldwide 
[9]. Meanwhile, 4% to 78% of selected patients with initially 
unknown epilepsy etiology have genetic variants of prob-
able or definitive etiologic significance [10]. The estimated 
proportion of individuals who carry a pathogenic variant 
that contributes substantially or causes epilepsy is approxi-
mately 17% of patients for epileptic encephalopathies, 5% 
of patients with genetic generalized epilepsies, and 2% for 
non-lesional focal epilepsies [11]. However, more than 50% 
of patients with developmental and epileptic encephalopa-
thies (DEEs) cannot be genetically diagnosed despite state-
of-the-art genetic testing techniques [9, 12].
In 2019, more than 140 epilepsy-associated genes or loci 
have been listed within the Online Mendelian Inheritance 
in Man database [13].
Familial analysis in epilepsy
Human genetics research has established that a genetic 
basis contributes to the susceptibility to epilepsy in most 
cases. However, the multifactorial condition of epilepsy 
that subsumes a variety of epilepsy types, seizures, levels 
of severity, and comorbidity has made it a core challenge 
to disentangle the genetic architecture for different types of 
epilepsy and to determine the specific genetic risks for each 
individual with epilepsy [14].
Early epilepsy gene discoveries used the strategy of as-
certaining very large families, typically with 10 or more af-
fected individuals, where the family history supported the 
presence of simple inheritance, and success utilizing para-
metric linkage analysis was likely [15]. This approach led to 
the recognition of a number of familial epilepsies and some 
of their genetic determinants. 
The epilepsy diathesis hypothesis suggested that a famil-
ial predisposition for epilepsy exists due to the inheritance 
of susceptibility variants. In support of this was the discov-
ery that rare inherited copy number variants can increase 
risk for different epilepsy syndromes [16].
Since the historical finding of a CHRNA4 mutation 
causing autosomal dominant sleep-related hypermotor epi-
lepsy (formerly known as autosomal dominant nocturnal 
frontal lobe epilepsy) in 1995 [17], discoveries of epilepsy 
genes have advanced greatly and accelerated further with 
the advent of next generation sequencing [10, 18].
Most genes identified to date come from monogenic 
families of focal epilepsies, and attempts to identify risk 
genes associated with genetic generalized epilepsies (GGE) 
have been largely unsuccessful [19]. Besides that, to date, 
reports from largescale Whole Exome Sequencing (WES) 
projects in epilepsy have focused mainly on cohorts with 
severe epilepsies of infancy and childhood, particularly the 
epileptic encephalopathies [20, 21]. These studies have re-
ported diagnostic, monogenic causes in almost 27% of cas-
es, identifiable via exome sequencing [22-24].
Fakhro et al. recently confirmed the benefit of working 
with families whose large sizes facilitate the assessment of 
multiple siblings [25]. The effect of adding siblings to the 
analysis of recessive variants was even more drastic than 
for de novo variation. Between 12 to 42% of recessive vari-
ants discovered in an index case were shared by a single sib-
ling, and only 1.3 to 11% were shared by two siblings. For 
families where there were 3 affected siblings, for example, 
GD001, the only variant remaining after filtration was the 
disease-causing variant. Conversely, in settings where sib-
lings do not share the phenotype, the additional siblings 
can help sort benign family-specific polymorphisms from 
bona fide disease variants [25]. At the same time, index cases 
may appear to have as many as 10 de novo protein-altering 
variants when compared only with their parents, requiring 
significant time and resource investment for experimental 
validation. Therefore, introduction of a single sibling will 
reduce that number by more than half, while introduction 
of two siblings reduced the mean number of high quality 
protein-altering de novo variants to 0.5 per individual, con-
sistent with previous reports [26].
Relatives of people with epilepsy have shown an increased 
incidence of epilepsy, even in families without Mendelian 
(monogenic) patterns of inheritance [27]. Moreover, stud-
ies on twins and families have shown that specific features 
of epilepsy are themselves heritable traits, including specific 
epilepsy syndromes [28], seizure types and symptoms [29], 
and EEG patterns [30]. Furthermore, the risk of epilepsy ap-
pears to be higher in the relatives of probands with gener-
alized epilepsy than in the relatives of probands with focal 
epilepsy [27].
 A lot of other, still incompletely studied family features 
may have genetic determinants that are distinct from the ge-
netic determinants of epilepsy per se, just as in a recent study 
that proved the age at seizure onset to be an independent fa-
milial trait, with possible genetic determinants distinct from 
the determinants of particular epilepsy syndromes [13]. 
Several novel genes and disorders associated with DEE 
have been identified in the last few years [31-33]. Many of 
the genes causing epilepsy encode components of neuronal 
ion channels leading to neuronal hyperexcitability or deple-
tion of inhibitory mechanisms [34, 35]. However, recently, 
several new genes coding for proteins other than ion chan-
nels have been identified, such as chromatin remodelers, 
intracellular signaling molecules, metabolic enzymes, tran-
scription factors, and mitochondrial complex genes [6, 36].
Genetic testing in epilepsy
Clinical features often drive the choice of a particular ge-
netic test or testing strategy, but in many patients, their pre-
sentation is not suggestive of a specific gene, or set of genes. 
WES and epilepsy panels (EP) are nowadays considered the 
most cost-effective genetic tests for epilepsy [37]. 
Gene panels provide a higher sequencing depth and 
lower cost when compared to the exome or genome se-
quencing, but restrict the diagnosis to specific genes in the 
panel, commercially available EPs typically targeting from 
70 to 465 genes [38].
Importantly, some large panels are now based on WES, 
with restricted analysis of only the “panel” genes, so the 
benefit of higher depth of coverage is lost, but this opens 
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up the possibility of future reanalysis to include the whole 
exome [12].
Considering the fact that copy-number variants (CNVs) 
contribute significantly to variation in the human genome 
and estimating that they cause 1.2% difference for every ref-
erence genome [39], previous recommendations used the 
stepwise chromosomal microarrays method (CMA) ± EP ± 
WES testing strategy in epilepsy. CNVs can be detected by 
several genomic methods including conventional karyotype 
(deletions/duplications >5 Mb), CMA (~100 kb–5 Mb) and/
or other methods, such as quantitative PCR and multiplex 
ligation-dependent probe amplification that target to detect 
smaller variations (<1 kb) [12].
Although less expensive, CMA has a lower diagnostic 
yield in epilepsy, and its use as the first-tier test is thus not 
anymore supported from a cost-effectiveness perspective 
[37]. However, in specific scenarios like epilepsy plus intel-
lectual disability, epilepsy plus autism spectrum disorder, 
epilepsy with dysmorphic features – CMA is still consid-
ered be the most cost-effective and clinically useful test [37]. 
Studies using CMA have shown that pathogenic CNVs ac-
count for 5–10% of childhood epilepsies including DEE [40, 
41]. Besides that, the most common types of genetic causes 
of DEE are sequence changes, responsible for 30–40% of 
cases, and chromosomal deletions or duplications, respon-
sible for 5-10% of cases [10, 42]. Thus, an individualized 
evaluation of cost-effectiveness based on prior diagnostic 
yields for each of the targeted populations and costs for each 
test should be considered that is expected to optimize the 
diagnostic yield and use of resource. It is worth mentioning 
that the diagnostic yield of copy number variants (CNVs) is 
better understood in paediatric epilepsy compared to adult 
patients with epilepsy [43, 44].
More recently, de novo mutagenesis has emerged as the 
major genetic mechanism in epileptic encephalopathies and 
rapid progress in identifying them has been facilitated by 
WES [45, 46].
An increasingly appreciated and clinically important 
subtlety for the de novo paradigm is the role of mosaicism 
– post-zygotic mutations not present in every cell in the 
body. This kind of somatic mosaicism might contribute 
to the phenotypic heterogeneity seen with many epilepsy 
genes [13]. This new genetic mechanism has been recently 
identified as playing a larger role in focal epilepsies than it 
was previously thought. The repeated expansions in intronic 
regions – identified as the cause of a familial epilepsy syn-
drome associated with myoclonus [47] and tremor [48] sug-
gest the role of these type of variants in epilepsies, an impor-
tant aspect that is not easily detected by current sequencing 
technologies, the vast non-coding portion of the genome 
(including intronic and intergenic regions) that are current-
ly explored in neurodevelopmental disorders and the analy-
sis of the regulatory regions (e.g., promoters and enhanc-
ers) in patients with autism and developmental delay [49]. 
Another aspect is represented by the genes, the mutations 
in which they evoke a range of different phenotypes, yet to 
be described, starting with complex, neonatal onset diseases 
at the severe end and a childhood onset at the milder end 
of the spectrum, including or excluding epilepsy from the 
picture, depending on the type of the mutation [50].
Another issue to be discussed is the use of Next 
Generation Sequencing (NGS) methods to identify dis-
ease-causing variants in poorly characterized populations 
that presents several challenges. For example, it was re-
cently discovered that up to 15% of “variants” detected in 
>1000 Arabian people when aligned to reference genome 
GRCh37/hg19 had a minor allele frequency (MAF) >50% 
in the same cohort and therefore should to be considered 
reference alleles for this population [51].
Despite all the previously mentioned challenges, the need 
to identify causative genes for genetic disorders is an urgent 
issue, given that Mendelian diseases on aggregate affect ~8% 
of live births and are the leading cause of morbidity and mor-
tality in children worldwide [52]. This also poses serious fi-
nancial burdens on healthcare systems – in the cases where 
healthcare intervention is available, the total cost of care over 
an individual’s lifetime may exceed $5 000 000 [53].
Whole Exome Sequencing in epilepsy
Over the last decade, NGS has significantly advanced the 
field of human genetics and genomics [54], leading to an 
explosion of gene discovery across many human disorders. 
The number of disease-associated genes has grown to 4132, 
and over 50 genes have been newly associated with epilepsy 
in the last three years alone [55].
It was previously established that WES, in combination 
with array-comparative genomic hybridization (aCGH), 
provides a diagnostic rate of 27% in unrelated adult epilepsy 
patients, 42% in unrelated paediatric patients, and 31% in a 
combined adult and paediatric cohort of unrelated patients 
with medically refractory epilepsy and co-morbid intellec-
tual disability, that indicates that WES has similar utility 
in both adult and paediatric cohorts and is appropriate for 
diagnostic testing in both epilepsy patient groups [56]. To 
date, the majority of diagnostic genetic testing is conducted 
in the paediatric population, while the utility of such testing 
is less well understood in adults with epilepsy. 
Another recent meta-analysis comprising more than 
20000 children proved the diagnostic and clinical utility of 
whole exome/genome sequencing to be greater than chro-
mosomal microarray alone, and that it should be considered 
as the first-line genomic test for children with suspected 
genetic diseases [57]. WES alone, judging on the previous 
studies, in mixed-age populations with multiple seizure 
types, has a diagnostic yield of 33–38% [10, 24, 58].
WES is not yet a match for CMA for CNV detection, as 
it can provide data about only the protein coding or exonic 
regions, but it is an increasingly powerful diagnostic tool, 
since a growing number of algorithms are being developed 
to aid the detection of CNVs by NGS and it is now pos-
sible to detect both single nucleotide variations (SNVs) and 
CNVs using an exome – or genome-wide approach with a 
single test [59].
A broad range in the diagnostic rate of WES in epilepsy 
has been described, the result of the variable definition of 
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each cohort depending on factors, such as type of epilepsy, 
phenotypic features, disease severity or prior genetic screen-
ing. In focal epilepsy, genetic diagnostic rate varies between 
12.5% of cases [60] to 43% of cases with epileptic encepha-
lopathy (EE) and in 33% of epilepsy cohort overall [10].
In 2011, the International League Against Epilepsy 
(ILAE) launched the Consortium on Complex Epilepsies, 
to facilitate meta-analysis in epilepsy genomics. In 2014, the 
first such meta-analysis was reported comprising 8696 cases 
and 26157 controls. This led to the identification of 2q24.3, 
4p15.1, and 2p16.1 as epilepsy loci [61].
A recent analysis of exome sequencing in unrelated indi-
viduals with a family history of epilepsy shows an increased 
burden of ultra-rare variants among the currently known 
epilepsy genes [62]. However, the relevance of variants in 
these genes to common epilepsies, where inheritance is 
complex, remains uncertain, and molecular genetics ad-
vances have been modest [63].
In 2016, Afawi Z. et al. published their results on 211 
families ascertained over an 11-year period in Israel, and 
pathogenic variants were identified in 49/211 families 
(23%). The majority were found in established epilepsy 
genes (e.g., SCN1A, KCNQ2, CSTB), however in 11 fami-
lies, this cohort contributed to the initial discovery (e.g., 
KCNT1, PCDH19, TBC1D24) [63].
In 2017, the Epi4K Consortium, assembled and analyzed 
a cohort of 303 families. These findings suggested that spe-
cific patterns of syndromic familial aggregation occur, in-
cluding newly recognized forms of familial focal epilepsy; 
although syndrome-specificity usually occurs in multiplex 
families, the one-third of families with features of both fo-
cal and generalized epilepsy is suggestive of shared genetic 
determinants; and that patterns of features observed across 
families including pedigree structure, sex, and age of onset 
may hold clues for future gene identification [64].
Recently, International League Against Epilepsy Con-
sortium on Complex Epilepsies, performed a Genome-
wide mega-analysis, and identified new 16 epilepsy loci. 
Importantly, 11 of these loci are associated with the genetic 
generalized epilepsies; the group of epilepsies where despite 
having the highest heritability there  were made the least 
genetic progress to date [65].
The largest exome study of epilepsies to date showed that 
deleterious ultra-rare variants (URVs) – variation absent in a 
large population-based exome database – is enriched across 
the severity spectrum for epilepsy syndromes, when indi-
viduals with these syndromes are compared to ancestrally 
matched controls. Specifically, they observed a significant 
excess of deleterious URVs in constrained genes, established 
epilepsy-associated genes, and GABAA receptor subunit 
genes, a larger group of genes delineating the GABAergic 
pathway, and also in all cation-channel-encoding genes. The 
evidence that URVs contribute partially to genetic general-
ized epilepsies and non-acquired focal epilepsies is clear, but 
what remains unclear is the extent to which the excess rate 
of URVs observed in individuals with epilepsy that  is a con-
sequence of a small subset of affected individuals carrying 
highly penetrant mutations or a result of URVs that confer 
risk, yet instead of rising to the level of Mendelian acting 
mutations, simply contribute to an overall polygenic risk for 
these syndromes [14].
Single gene causes of the more common forms of epi-
lepsy appear to be relatively rare [64]. These common forms 
are likely multifactorial, with a significant and complex ge-
netic architecture [66]. Solving the genetic architecture of 
common complex diseases remains a major challenge in 
the genetics field, since these findings might highlight that 
genes commonly involved in epilepsy span a wider range of 
epilepsy phenotypes than previously assumed [67].
Despite recent molecular advances in epilepsy, ge-
netic investigation is often overlooked in adult practice. 
Diagnostic yields of different genetic testing methods have 
not yet been established for adult epilepsy patients. Further 
studies  including larger population samples could be aimed 
to assess more prevalent genes related to epilepsy in adult-
hood, and whether these are similar to or different from 
those previously reported in paediatric cohorts [68]. Less 
is known about the diagnostic yield of WES in adult epi-
lepsy populations, and it is unknown if adult patients with 
epileptic encephalopathy who survive into adulthood have 
a different genetic etiology compared to a paediatric patient 
cohort [56].
The reanalysis can increase the diagnostic yield in larger 
cohorts. Re-analysis and diagnosis are particularly impor-
tant in epilepsy due to the rapid rate of gene discovery and 
potential for treatment implications [10]. For example, re-
cently, a study identified intragenic, multi-exon deletions in 
TANGO2 by reanalysis of ES data [69, 70].
The Epilepsy Genetics Initiative (EGI) was formed in 
2014 to create a centrally managed database of clinically 
generated exome sequence data. EGI performs systematic 
research-based reanalysis to identify new molecular diag-
noses that were not possible at the time of initial sequencing 
and to aid in novel gene discovery. They recently showed 
a diagnostic rate of 5.8% in previously negative cases – a 
considerable increase in diagnostic yield demonstrating the 
value of periodic reinterrogation of whole exome data [8].
Whole Genome Sequencing (WGS) is increasingly being 
used to uncover the role of non-coding genetic material in 
the human genome [71, 72]. 
Several studies have proposed a genetic testing strategy 
to achieve the highest clinical utility, cost-effectiveness, and 
diagnostic yield for individuals with epilepsy [24, 37, 73], 
but specific testing algorithms are likely to change over time 
as new tests are introduced and the costs of existing tests de-
crease. New assays may be required to detect lesser-known 
but important molecular mechanisms [12].
Risk prediction in epilepsy
For most common epilepsies not caused by a single gene 
mutation, the relative risk to first-degree family members 
is 6–8 times greater for generalized epilepsy and 2–3 times 
greater for focal epilepsy, relative to a baseline cumulative 
incidence around 1% by age 20 years [27].
If a dominant monogenic cause is identified by genetic 
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testing, or strongly suspected from the family history, then 
a recurrence risk approaching 50% is expected (slightly re-
duced by incomplete penetrance, which is approximately 
60–80% for most dominant Mendelian epilepsies) [74]. For 
children with de novo mutations, the recurrence risk in sib-
lings should theoretically be zero. However, parental mosa-
icism elevates that risk and might be more common than 
previously suspected [7].
Among relatives of all probands (patient zero with epi-
lepsy), cumulative incidence of epilepsy up to the age of 40 
is 4.7%, and the risk shows a 3.3-fold increase compared 
with population incidence. The risk is largely higher in rela-
tives of probands with idiopathic generalized epilepsies and 
epilepsies associated with intellectual or motor disability 
presumably present since birth (‘prenatal/developmental 
cause’). Among relatives of probands with epilepsy without 
an identified cause (including epilepsies classified as ‘idio-
pathic’ or ‘unknown cause’), the risk was significantly higher 
for epilepsy of prenatal/developmental cause. In relatives of 
probands with generalized epilepsy, standardized incidence 
ratios were 8.3 for generalized epilepsy and 2.5 for focal epi-
lepsy. In relatives of probands with focal epilepsy, standar-
dized incidence ratios were 1.0 for generalized epilepsy and 
2.6 for focal epilepsy [27].  
Gender analysis showed that  epilepsy incidence was 
greater in offspring of female probands than in offspring of 
male probands, and this “maternal effect” was restricted to 
offspring of probands with focal epilepsy [75].
The results suggest that risks for epilepsies of unknown 
and prenatal/developmental cause may be influenced by 
shared genetic mechanisms. They also suggest that some 
of the genetic influences on generalized and focal epilep-
sies are distinct. However, a similar increase in risk for focal 
epilepsy among relatives of probands with either general-
ized (2.5-fold) or focal epilepsy (2.6-fold) may reflect some 
coexisting shared genetic influences [27].
In addition to single-gene Mendelian inheritance, there 
is an ample evidence for gene variants conferring risk of dis-
ease due to variable alterations in cellular function, some-
times modulated by other genes or epigenetic and environ-
mental cues [76]. Consequently, many variants occur among 
population with minor degrees of potential influence on 
disease. Separately, they might not be enough to cause the 
disease in most circumstances. They would rather probably 
affect health by altering the risk of sporadic disease, in com-
bination with other factors. Additional research is needed 
to realize the potential of linking strategies for genetic risk 
assessment to disease prevention and therapy.
Limitations, such as referral and reporting biases, small 
sample size, ambiguous disease definitions in probands and 
relatives, lack of controls, and failure to control adequately 
for age in the relatives should be considered when interpre-
ting historical genetic studies in epilepsy.
Precision medicine in epilepsy
There are ample data to support the use of next-gener-
ation sequencing in reducing the patient’s time to diagno-
sis, often referred to as the “diagnostic odyssey”. Precision 
health encompasses the use of patient-specific data to tailor 
patient-specific care [77].
We are now entering the era of genomics-driven person-
alized medicine, whereby novel treatments can be designed 
which are not solely symptomatic, but address the underly-
ing cause of the epilepsy in the individual person and offer 
opportunities for truly disease modifying effects [78].
An increasing body of evidence indicates that identify-
ing the pathogenic variant in individual patients with ge-
netic epilepsies is relevant not only for diagnosis and prog-
nosis, but also for treatment selection [79, 80]. This finding 
is not surprising, because responses to specific treatments 
can vary depending on the disease’s underlying mechanisms 
which, in turn, may differ even across individuals sharing 
the same phenotype [6].
Precision approaches have also helped progress in the 
diagnosis and treatment of epilepsy syndromes. For ex-
ample, in genetic epilepsy syndromes due to single-gene 
Mendelian mutations (about 1% of paediatric epilepsies), 
the efficacy of specific anti-epileptic drugs can be directly 
related to the underlying mutation, as is the case in Dravet 
syndrome, for which treating patients with sodium channel 
blockers is contraindicated [81]. Also, a more recent report 
of Kim et al. [32] described the discovery, development, 
and administration of an antisense oligonucleotide (ASO) 
therapy specifically designed for a single patient with CLN7 
neuronal ceroid lipofuscinosis (a form of Batten’s disease), a 
fatal genetic neurodegenerative disorder. The most remar-
kable is the fact that some neurological diseases, previously 
of unknown etiology, are nowadays proved as being treat-
able, without too much effort, as in case of vitamin B6 utility 
in neuropathies characterized by reduced PLP levels [82].
Reaching a genetic diagnosis in epilepsy may modify 
treatment, although this occurs in a minority of cases. The 
most frequent benefits of a genetic diagnosis of epilepsy are 
difficult to quantify, though this  might include the answer 
to what is causing the disease, the ability to search for other 
symptoms associated with the gene variant, additional prog-
nostic information, a sense of belonging to a specific sup-
port group for the families, informed reproductive choices, 
and possibly enrollment in clinical trials that are genotype 
specific [41].
Common problems in refractory epilepsy include the 
challenges of trial-and-error drug selection that can result 
in undesirable polytherapy, seizure-related injury, side ef-
fects, cost and even the development of some structural 
changes under the influence of the medication in some pa-
tients [60, 83-85].
The advanced knowledge of the molecular mechanisms 
leading to the development of epilepsy and its comorbidities 
might facilitate the patients’ management by applying truly 
personalized therapies. Rather than relying on empirical ob-
servations relating genotypes to response to specific drugs, 
further prevailing paradigms will involve characterization 
of the functional consequences of the pathogenic gene vari-
ant and thus searching for available treatments that could 
correct the specific dysfunction responsible for the manifes-
tations of the disease in each individual patient [86].
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If no available treatment is identified, then new treatments 
may be designed and developed to address the pathogenic de-
fect or the resulting functional abnormalities [6, 78, 87]. The 
alternative to drug repurposing consists in developing totally 
novel treatments, which can be designed once the mecha-
nisms of the disease have been sufficiently characterized. The 
development of effective therapies for genetic CNS disorders 
is facilitated by advances in gene therapies, sense and anti-
sense oligonucleotides, and other innovative therapeutics [6, 
88, 89]. Applied research in this area also benefits from im-
proved understanding of structure-activity relationships, and 
from access to 3D structural information on thousands of 
protein molecules through the Protein Data Bank [90].
The availability of animal models, which reproduce 
the targeted genetic defect is especially highly valuable to 
streamline preclinical development [91, 92].
Finally yet importantly, the application of pharmacoge-
netics to treatment and diagnosis extends beyond epilepsy 
and is a clinical area that is still under development. Over 
time, the use of patient,s genetic data to predict drug efficacy 
and minimize side-effects will probably expand as research 
into these areas progresses. With unprecedented amounts of 
human data being generated from patients and healthy in-
dividuals, coupled with major developments in technology 
and large-scale data analysis, advances in genomics and pre-
cision health are creating new opportunities for evidence-
based and patient-centered care. The next decade provides 
major shifts in the translation of these technologies into the 
clinical setting that will certainly benefit patients with neu-
rological diseases.
Conclusions
Epilepsy’s genetic background is nowadays undeniable; 
more than 140 genes or loci being already associated with 
this worldwide spread disease. However, the complexity of 
this health burden makes it a challenge to rapidly determine 
the cause and to pursue the best treatment management.
It is already proved that relatives of people with epilepsy 
have an increased risk to develop epilepsy, even in families 
without Mendelian inheritance. 
Whole Exome Sequencing (WES) and epilepsy panels 
(EP) are nowadays considered the most cost-effective ge-
netic tests for epilepsy, though the familial genetic analysis 
is an approach that could furthermore reduce the epilepsy 
patient’s “diagnostic odyssey”, by increasing the chances of 
identifying the truly disease-causing variant after filtration. 
Despite recent molecular advances in epilepsy, genetic 
investigation is often overlooked in adult practice and much 
more details should be considered when interpreting his-
torical genetic studies in epilepsy.
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